Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERATE: Tirzepatide for Binge-Eating Disorder and Obesity
NCT06847399Phase 2Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tirzepatide in binge eating disorder (BED) and obesity (3 arms), sponsored by Johns Hopkins University. Primary endpoints: Percent initial weight loss at 52 weeks and Change in the Number of Binge-eating episodes at 52 weeks. Started Sep 2025; status: recruiting.
02
Drugs
03
Conditions
binge eating disorder (BED)obesity
Beyond the preview
Go deeper on NCT06847399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06847399.